Gastrointestinal Stromal Tumor Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Arog Pharmaceuticals, Taiho Pharmaceuticals, Cogent Biosciences, Inc., Plexxikon

The Gastrointestinal Stromal Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastrointestinal Stromal Tumor pipeline products will significantly revolutionize the Gastrointestinal Stromal Tumor market dynamics.

DelveInsight's "Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gastrointestinal Stromal Tumor market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market Insights
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Overview
As per GIST Support International, Gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs. GIST progression is driven by mutations in KIT or PDGFRA or by other rare gene alterations, all of which are mutually exclusive.

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report:
• The Gastrointestinal Stromal Tumor market size was valued at USD 437 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total incident cases of Gastrointestinal Stromal Tumor in the year 2021 were estimated to be 14,663 cases in 7MM
• The total incident cases of GIST based on mutation are categorized into KIT mutation, PDGFRA mutation, BRAF mutation, and others. In the assessment, it was found that in 2021, there were 11,584 incident cases of KIT mutation, 1,580 cases of PDGFRA mutation, 133 cases of BRAF mutation, and 1,367 cases of other mutation in the 7MM
• it was found that in 2021, there were 3,815incident cases in the localized stage, 942 cases in the regional stage, 1,255 cases in the distant stage, and265cases in the unknown stage in the United States
• Key Gastrointestinal Stromal Tumor Companies: Arog Pharmaceuticals, Taiho Pharmaceuticals, Cogent Biosciences, Inc., Plexxikon, Bristol-Myers Squibb, Pfizer Inc., Array BioPharma, Ariad Pharmaceuticals, and others
• Key Gastrointestinal Stromal Tumor Therapies: Crenolanib, TAS-116, Bezuclastinib, Opdivo With/Without Yervoy, MEK162 in Combination With Imatinib Mesylate, Iclusig (Ponatinib), and others
• The Gastrointestinal Stromal Tumor epidemiology based on gender analyzed that males accounted for a larger proportion of about 52% of total incident cases

Get a Free sample for the Gastrointestinal Stromal Tumor Market Report
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key benefits of the Gastrointestinal Stromal Tumor Market report:

1. Gastrointestinal Stromal Tumor market report covers a descriptive overview and comprehensive insight of the Gastrointestinal Stromal Tumor Epidemiology and Gastrointestinal Stromal Tumor market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Gastrointestinal Stromal Tumor market report provides insights on the current and emerging therapies.
3. Gastrointestinal Stromal Tumor market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Gastrointestinal Stromal Tumor market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Gastrointestinal Stromal Tumor market.

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiological Insights
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Market
The dynamics of the Gastrointestinal Stromal Tumor market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Gastrointestinal Stromal Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastrointestinal Stromal Tumor Epidemiology Segmentation:
The Gastrointestinal Stromal Tumor market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Gastrointestinal Stromal Tumor
• Prevalent Cases of Gastrointestinal Stromal Tumor by severity
• Gender-specific Prevalence of Gastrointestinal Stromal Tumor
• Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Gastrointestinal Stromal Tumor market share @ Gastrointestinal Stromal Tumor market forecast
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Therapies and Key Companies
• Crenolanib: Arog Pharmaceuticals
• TAS-116: Taiho Pharmaceuticals
• Bezuclastinib: Cogent Biosciences, Inc./ Plexxikon
• Opdivo With/Without Yervoy: Bristol-Myers Squibb
• MEK162 in Combination With Imatinib Mesylate: Pfizer Inc/ Array BioPharma
• Iclusig (Ponatinib): Ariad Pharmaceuticals

Gastrointestinal Stromal Tumor Market Drivers
• Rich emerging pipeline
• Increasing incidence
• Understanding of pathophysiology
• Increased awareness
• Identification of solid tumor's treatment with NTRK gene fusions

Scope of the Gastrointestinal Stromal Tumor Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastrointestinal Stromal Tumor Companies: , and others
• Key Gastrointestinal Stromal Tumor Therapies: Crenolanib, TAS-116, Bezuclastinib, Opdivo With/Without Yervoy, MEK162 in Combination With Imatinib Mesylate, Iclusig (Ponatinib), and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastrointestinal Stromal Tumor Unmet Needs, KOL's views, Analyst's views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

Gastrointestinal Stromal Tumor Market Barriers
• Resistance against pharmacological therapies
• Clinical challenges in the management of disease
• High economic burden
• Side effects and adverse events after treatment

Table of Contents
1. Gastrointestinal Stromal Tumor Market Report Introduction
2. Executive Summary for Gastrointestinal Stromal Tumor
3. SWOT analysis of Gastrointestinal Stromal Tumor
4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance
5. Gastrointestinal Stromal Tumor Market Overview at a Glance
6. Gastrointestinal Stromal Tumor Disease Background and Overview
7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor
9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices
10. Gastrointestinal Stromal Tumor Unmet Needs
11. Gastrointestinal Stromal Tumor Emerging Therapies
12. Gastrointestinal Stromal Tumor Market Outlook
13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2019-2032)
14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies
15. Gastrointestinal Stromal Tumor Market Drivers
16. Gastrointestinal Stromal Tumor Market Barriers
17. Gastrointestinal Stromal Tumor Appendix
18. Gastrointestinal Stromal Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Gastrointestinal Stromal Tumor treatment, visit @ Gastrointestinal Stromal Tumor Medications https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:
Gastrointestinal Stromal Tumor Pipeline https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Gastrointestinal Stromal Tumor Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastrointestinal Stromal Tumor market. A detailed picture of the Gastrointestinal Stromal Tumor pipeline landscape is provided, which includes the disease overview and Gastrointestinal Stromal Tumor treatment guidelines.
Gastrointestinal Stromal Tumor Epidemiology https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gastrointestinal Stromal Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.